Leadership & Management Team

Elizabeth Ofili
Founder and Chairman of the Board, AccuHealth Technologies, Inc., Atlanta, GA.
Dr Ofili has over twenty years experience as a cardiologist and clinician scientist. She is lead inventor of the patent and trademark for a method and system for chronic illness care that integrates each individual’s risk factors and co-morbidities to develop and implement personalized, preventive, participatory and predictive health and wellness. Through self monitoring, feedback and guidance from a personal health coach, the technology empowers patients to achieve sustained behavior change and medication adherence for difficult to treat patients with hypertension, diabetes and other chronic health conditions. Dr Ofili has national and international recognition as a clinician scientist with particular focus on cardiovascular disparities and women’s health. She has been continuously funded by the NIH and industry/foundations since 1994, with a track record in clinical trials that impact health disparities. She has raised over $100 million in research funds: including direct contribution to the growth and expansion of clinical and translational research portfolio at MSM: from $1 million/year in 2000 to over $6 million per year in 2012, including NIH awards and industry awards. She directly contributed to the growth and expansion of training programs that support clinicians and biomedical scientists, including predoctoral and postdoctoral trainees; from zero clinical and translational research training programs in 2000 to 5 training programs in 2012, totaling $1.3 million/year in new funding. As president of the Association of Black Cardiologists (2000-2002), Dr Ofili led the organization to partner in a pioneering clinical trial called the African American Heart Failure Trial(AHEFT) which discovered a new treatment for heart failure, leading to a change in clinical practice guidelines for the treatment of African American patients with heart failure, and continues to impact heart failure outcomes and survival. Dr Ofili serves as a professor of medicine, chief of cardiology and associate dean for clinical research at Morehouse School of Medicine, Atlanta Georgia. She is the senior principal investigator of the Atlanta Clinical and Translational Science Institute (ACTSI), a three institution clinical and translational science award (CTSA) from the National Institutes of Health, that engages faculty and scientists from Emory University, Morehouse School of Medicine and Georgia Institute of Technology. The ACTSI supports innovations in scientific discovery, training and community engagement that impact the broader Atlanta community. She serves on the Executive Board of
Nathan Saint Clair, BA Informatics
Chief Technology Officer, AccuHealth Technologies, Inc., Atlanta, GA.
He graduated from the top ranked University of Washington with a B.A. in Informatics. He has over 15 years of experience in software engineering with particular emphasis in Healthcare systems, Personal Health Records, & Electronic Health Records and health data interoperability. With more than 10 years on the forefront of innovative mobile and healthcare related technologies, he believes the purpose of technology is to enable visions, drive productivity, and transform lives for the better.

Louis Sullivan, MD
Advisory Board, AccuHealth Technologies, Inc., Atlanta, GA.
Louis Sullivan, MD, PhD is chairman of the board of the National Health Museum in Atlanta, Georgia, whose goal is to improve the health of Americans by enhancing health literacy and advancing healthy behaviors. He also is chairman of the Washington, D.C.-based Sullivan Alliance to Transform America’s Health Professions. He was the founding dean and first president of Morehouse School of Medicine and is now President Emeritus. He served as chair of the President’s Commission on Historically Black Colleges and Universities from 2002-2009, and was co-chair of the President’s Commission on HIV and AIDS from 2001-2006. With the exception of his tenure as secretary of the U.S. Department of Health and Human Services (HHS) from 1989 to 1993, Dr. Sullivan was president of Morehouse School of Medicine (MSM) for more than two decades. On July 1, 2002, he retired and was appointed president emeritus. He continues to support the school, including its national fund-raising activities. Dr. Sullivan became the founding dean and director of the Medical Education Program at Morehouse College in 1975. The program became The School of Medicine at Morehouse College in 1978, admitting its first 24 students to a two-year program in the basic medical sciences. In 1981, the school received provisional accreditation of its four year curriculum leading to the M.D. degree, became independent from Morehouse College and was re-named Morehouse School of Medicine, with Dr. Sullivan as dean and president. In 1983, MSM became a member of the Atlanta University Center (AUC). MSM was fully accredited as a four-year medical school in April 1985 and awarded its first 16 M.D. degrees in May of that year. Dr. Sullivan left MSM in 1989 to accept an appointment by President George H.W. Bush to serve as secretary of HHS. In this cabinet position, Dr. Sullivan managed the federal agency responsible for the major health, welfare, food and drug safety, medical research and income security programs serving the American people. His efforts to improve the health and health behavior of Americans included (1) the introduction of a new and improved FDA food label; (2) the release of Healthy People 2000, a guide for improved health promotion/disease prevention activities; (3) educated the public about the health dangers from tobacco use; (4) led the successful efforts to prevent the introduction of “Uptown,” a non-filtered, mentholated cigarette; (5) inaugurated a $100 million minority male health and injury prevention initiative; and (6) implemented greater gender and ethnic diversity in senior positions of HHS, including the appointment of the first female director of the National Institutes of Health, the first female (and first Hispanic) Surgeon General of the U.S. Public Health Service, the first African American Commissioner of the Social Security Administration, and the first African-American Administrator of the Health Care Financing Administration. In January 1993, he returned to MSM and resumed the office of president. In March 2008, Dr. Sullivan was appointed to the new Grady Hospital Corporation Board of Trustees. In June, 2008, Dr. Sullivan accepted appointments to (a) the Health Disparities Technical Expert Panel (HDTEP) of the Centers for Medicare and Medicaid Services (CMS) of HHS and (b) an Institute of Medicine Committee, “Improving the Organization of the U.S. Department of Health and Human Services to Advance the Health of Our Population.”
David Satcher, MD, PhD
Advisory Board, AccuHealth Technologies, Inc., Atlanta, GA.
Dr. David Satcher, MD, PhD, is the Poussaint-Satcher-Cosby Chairman in mental health and Director of the Satcher Health Leadership Institute at Morehouse School of Medicine . Dr Satcher was the 16th Surgeon General of the United States (1998-2002), and he became the second person in history to ever simultaneously hold the positions of Surgeon General and Assistant Secretary for Health. He was President of Morehouse School of Medicine from December 2004 to July 2006. From 1993 to 1998, Dr. Satcher served as Director of the Centers for Disease Control and Prevention and Administrator of the Agency of Toxic Substances and Disease Registry. From September 2002 to December 2004, he served as Director of the National Center for Primary Care of Morehouse School of Medicine. He was the President of Meharry Medical College in Nashville, Tennessee from 1982 to 1993. He serves on the Boards of Action for Healthy Kids, American Foundation for Suicide Prevention, Kaiser Family Foundation, the Community Foundation of Greater Atlanta, the United Way of Atlanta and Task Force for Child Survival and Development. He serves as Co-Chair of the Advisory Committee on Public Issues of the Ad Council. He has served as a Commissioner on social determinants of health of the World Health Organization since 2005. He is a Fellow of the American Academy of Family Physicians, the American College of Preventive Medicine and American College of Physicians. He was a Senior Visiting Fellow with the Kaiser Family Foundation until September 2002. He received more than 40 honorary degrees and numerous distinguished honors, including the Jimmy and Rosalynn Carter Award for Humanitarian Contributions to the Health of Humankind, the New York Academy of Medicine Lifetime Achievement Award and the National Association of Mental Illness Distinguished Service Award. In 2005, he was the recipient of the American Cancer Society Humanitarian Award. A Morehouse College graduate, he is a former Robert Wood Johnson Clinical Scholar and Macy Faculty Fellow. he received both MD and PhD degrees from Case Western University in 1970, with election to the Alpha Omega Alpha Honor Society.
Louis Lange, MD, PhD
Advisory Board, AccuHealth Technologies, Inc., Atlanta, GA.
Louis Lange, MD, PhD, is currently a partner with Asset Management Company, a venture capital firm that he joined in June 2009. He founded CV Therapeutics and as Chairman, CEO and Chief Scientific Officer, he led the IPO in 1996 and the overall pipeline development and the initiatives for US FDA and European EMEA approval for Ranexa®, a first-in-class late sodium channel blocker and the first anti-anginal drug class approved in 30 years in the US. I also led the approval of Lexiscan®, a first-in-class adenosine A2a receptor agonist for use in myocardial perfusion imaging studies. He oversaw the commercial success of CV Therapeutics and its sale to Gilead in 2009 for $1.4 billion dollars. Dr. Lange has served as a trustee on the University of Rochester Board of Trustees since May 1997 and was a member of the governing body of the Emerging Company Section of the Biotechnology Industry Organization from 1999 to 2009. From 1980 to 1992, Dr. Lange served on the faculty of Washington University School of Medicine, including as Chief of Cardiology at Jewish Hospital in St. Louis, Missouri from 1985 to 1992, and as a full Professor of Medicine from 1990 until 1992. Dr. Lange holds an M.D. from Harvard Medical School and a Ph.D. in biological chemistry from Harvard University. He has over 22 years experience in academic medicine at Harvard Medical School and Washington University, and was one of the first academicians in molecular cardiology. Dr Lange is Chairman of the Board, Institute for Systems Biology, and a Senior Advisor at Gilead.
James R. Gavin III, M.D., Ph.D
Advisory Board, AccuHealth Technologies, Inc., Atlanta, GA
Dr. Gavin, Clinical Professor of Medicine, Emory University School of Medicine, Atlanta

James R. Gavin III, M.D., Ph.D., graduated from Livingstone College in Salisbury, N.C., in 1966 with a degree in chemistry. He earned his Ph.D. in biochemistry from Emory University in 1970 and his M.D. degree from Duke University School of Medicine in 1975.
Dr. Gavin is Clinical Professor of Medicine, Emory University School of Medicine, Atlanta, GA and Clinical Professor of Medicine, Indiana University School of Medicine. He was president of the Morehouse School of Medicine, Atlanta, GA from 2002-2004. He served as senior scientific officer at the Howard Hughes Medical Institute (HHMI) from 1991-2002 and director of the HHMI-National Institutes of Health Research Scholars Program from 2000-2002.
Before joining the senior staff of HHMI, he was on faculty at the University of Oklahoma Health Sciences Center as a professor of medicine and chief of the Diabetes Section, acting chief of the Section on Endocrinology, Metabolism and Hypertension, and William K. Warren Professor for Diabetes Studies. He previously served as Associate Professor of Medicine at Washington University School of Medicine in St. Louis. He was a lieutenant commander in the U.S. Public Health Service from 1971-73 and continues to serve as a reserve officer in the USPHS.
Dr. Gavin belongs to a number of organizations, including the Institute of Medicine of the National Academy of Sciences, the American Diabetes Association, the American Society of Clinical Investigation, the American Association of Physicians, the Alpha Omega Alpha Medical Honor Society, the Association of Black Cardiologists, Omicron Delta Kappa Honorary Society and the Sigma Pi Phi Leadership Fraternity. He is a past president of the American Diabetes Association and was voted Clinician of the Year by ADA in Diabetes in 1991. He has served on many advisory boards and on the editorial boards of the American Journal of Physiology and the American Journal of Medical Sciences. He is on the board of trustees for Emory University, Livingstone College, and the Robert Wood Johnson Foundation. He is a member of the Board of Baxter International, Inc., Amylin Pharmaceuticals, and Nuvelo Pharmaceuticals, Inc.. He is national program director of Harold Amos Faculty Development Program of the Robert Wood Johnson Foundation. Dr. Gavin is immediate past chairman of the National Diabetes Education Program and a past member of the Advisory Council to the NIDDK. He is also chairman of the Data Safety Monitoring Board for the VA Cooperative Diabetes Study.
He has published more than 200 articles and abstracts in such publications as Science, Journal of Applied Physiology, Diabetes, and the American Journal of Physiology
Among the many honors Dr. Gavin has received are the Daniel Hale Williams Award, the E.E. Just Award, the Herbert Nickens Award, the Daniel Savage Memorial Award, the Emory University Medal for Distinguished Achievement, the Banting Medal for Distinguished Service from the American Diabetes Association, the Distinguished Alumni Award from the Duke University School of Medicine, and the Internist of the Year from the National Medical Association.
Dr. Gavin and his wife, Annie, have been married for 37 years and they have three adult sons.
Chamberlain I. Obialo, MD
Chief Scientific Officer, Advisory Board Member, AccuHealth Technologies
Dr. Obialo is currently a Professor of Medicine, Chief of Nephrology and the Director of Dialysis at Morehouse School of Medicine, Atlanta, Georgia. He had his pre-med education at University Tutorial College London, England where he majored in Physics, Chemistry and Zoology. After attendeding Medical School in Nigeria where he graduated in 1979 with multiple distinctions, he completed Internal Medicine Training at St. Thomas Hospital, London and Oral Roberts University, Tulsa, Oklahoma. He then completed a fellowship in Nephrology at Washington University Medical School, St. Louis, Missouri where he then worked as an instructor of Medicine at Washington University Medical School 1990-1992. After moving to Gadsden, Alabama, where he served the Quality of Life Health Services Community for 2 years, he accepted a position at Morehouse School of Medicine in Atlanta, Georgia. Dr. Obialo is certified in both Internal Medicine and Nephrology; he has written over 50 published manuscripts and abstracts in prestigious medical journals such as: Nephron, American Journal of Kidney Disease, Kidney International, American Journal of Hypertension, Archives of Internal Medicine, American Journal of Cardiology, Journal of American Society of Nephrology, American Journal of Nephrology, Ethnicity and Disease and Journal of the National Medical Association. He is a Principal Investigator in many research studies involving Kidney Diseases, Hypertension, Anemia of Kidney Disease and Adherence in Dialysis. Not only is he on the editorial Board of several journals on Kidney Diseases, he was elected specialist in Hypertension by the American Society of Hypertension in 1999. He is a fellow of the American College of Physicians and a fellow of the American Society of Nephrology and has served as a Steering Committee member of KEEP [ Kidney Early Evaluation Program of the National Kidney Foundation]. In 2001, he was named one of America’s 100 leading Black Physicians by the Black Enterprise Magazine.
Ed Schutter, BS, MBA
Member, Advisory Board of AccuHealth Technologies.
Ed Schutter is a thirty year veteran of pharmaceutical industry currently serving as President and CEO of Arbor Pharmaceuticals. Arbor generates over $200 million in annual sales and has seven branded and over twenty-five generic products in development. Prior to Arbor, Ed served as President of Sciele Pharmaceuticals which sold to Shionogi & Co. Ltd. for $1.4 billion in 2008. In addition to his investment in Arbor, Ed is currently an angel investor in several biotech, branded and generic pharmaceutical companies in the U.S. and Canada